Latest News and Press Releases

BASEL, Switzerland, June 1, 2004 (PRIMEZONE) -- In his presentation to shareholders today, Anthony Man MD, Basilea's CEO, reflected on the 2003 business year as follows: "We achieved our ambitious...

BASEL, Switzerland, May 25, 2004 (PRIMEZONE) -- Basilea Pharmaceutica today announced gaining the global marketing and manufacturing rights for BAL5788 following Roche's decision not to exercise its...

BASEL, Switzerland, May 03, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG presented in vitro data yesterday at the 14th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),...

BASEL, Switzerland, March 3, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced positive phase II results for BAL5788 in the indication of complicated skin and skin structure infections...

BASEL, Switzerland, Feb. 24, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced the successful completion of phase I development for BAL8557, a novel water-soluble azole suitable for both...

BASEL, Switzerland, Feb. 12, 2004 (PRIMEZONE) -- Pharmaceutica Ltd announced today that it has appointed Professor Jutta Heim as Chief Scientific Officer and Dr. Ingrid Heinze-Krauss as Chief...

BASEL, Switzerland, March 21, 2003 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announced today that its double-blind, placebo-controlled, randomized, dose finding study of BAL4079 in patients with...

BASEL, Switzerland, March, 10, 2003 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. today announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its...